These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 25072631)
1. Improved efficacy and reduced toxicity of doxorubicin encapsulated in sulfatide-containing nanoliposome in a glioma model. Lin J; Shigdar S; Fang DZ; Xiang D; Wei MQ; Danks A; Kong L; Li L; Qiao L; Duan W PLoS One; 2014; 9(7):e103736. PubMed ID: 25072631 [TBL] [Abstract][Full Text] [Related]
2. Enhanced antitumor efficacy and reduced systemic toxicity of sulfatide-containing nanoliposomal doxorubicin in a xenograft model of colorectal cancer. Lin J; Yu Y; Shigdar S; Fang DZ; Du JR; Wei MQ; Danks A; Liu K; Duan W PLoS One; 2012; 7(11):e49277. PubMed ID: 23145140 [TBL] [Abstract][Full Text] [Related]
3. Intracellular drug delivery by sulfatide-mediated liposomes to gliomas. Shao K; Hou Q; Duan W; Go ML; Wong KP; Li QT J Control Release; 2006 Oct; 115(2):150-7. PubMed ID: 16963144 [TBL] [Abstract][Full Text] [Related]
4. Preparation of Liposome Gel by Calcium Cross-Linking Induces the Long-Term Release of DOX to Improve the Antitumor Effect. Wang L; Wang Y; Ye Z; Yu Y; Wang C; Qiu L; Du X; Zhou S; Wang J; Jiang P Mol Pharm; 2024 May; 21(5):2394-2405. PubMed ID: 38647653 [TBL] [Abstract][Full Text] [Related]
5. Environmentally Self-Adaptative Nanocarriers Suppress Glioma Proliferation and Stemness via Codelivery of shCD163 and Doxorubicin. Liu J; Zhang Y; Chen T; Chen H; He H; Jin T; Wang J; Ke Y ACS Appl Mater Interfaces; 2020 Nov; 12(47):52354-52369. PubMed ID: 33196179 [TBL] [Abstract][Full Text] [Related]
6. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity. Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502 [TBL] [Abstract][Full Text] [Related]
7. Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas. Chen H; Qin Y; Zhang Q; Jiang W; Tang L; Liu J; He Q Eur J Pharm Sci; 2011 Sep; 44(1-2):164-73. PubMed ID: 21782939 [TBL] [Abstract][Full Text] [Related]
8. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity. Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899 [TBL] [Abstract][Full Text] [Related]
9. cRGD-functionalized reduction-sensitive shell-sheddable biodegradable micelles mediate enhanced doxorubicin delivery to human glioma xenografts in vivo. Zhu Y; Zhang J; Meng F; Deng C; Cheng R; Feijen J; Zhong Z J Control Release; 2016 Jul; 233():29-38. PubMed ID: 27178807 [TBL] [Abstract][Full Text] [Related]
10. Surface-Modified Nanoerythrocyte Loading DOX for Targeted Liver Cancer Chemotherapy. Wang Y; Chen X; He D; Zhou Y; Qin L Mol Pharm; 2018 Dec; 15(12):5728-5740. PubMed ID: 30359027 [TBL] [Abstract][Full Text] [Related]
11. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q J Pharm Sci; 2005 Aug; 94(8):1782-93. PubMed ID: 15986461 [TBL] [Abstract][Full Text] [Related]
12. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. Siegal T; Horowitz A; Gabizon A J Neurosurg; 1995 Dec; 83(6):1029-37. PubMed ID: 7490617 [TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier. Lu J; Zhao W; Huang Y; Liu H; Marquez R; Gibbs RB; Li J; Venkataramanan R; Xu L; Li S; Li S Mol Pharm; 2014 Nov; 11(11):4164-78. PubMed ID: 25265550 [TBL] [Abstract][Full Text] [Related]
14. PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma. Xiao K; Luo J; Li Y; Lee JS; Fung G; Lam KS J Control Release; 2011 Oct; 155(2):272-81. PubMed ID: 21787818 [TBL] [Abstract][Full Text] [Related]
15. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect. Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193 [TBL] [Abstract][Full Text] [Related]
16. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy. Paliwal SR; Paliwal R; Mishra N; Mehta A; Vyas SP Curr Cancer Drug Targets; 2010 May; 10(3):343-53. PubMed ID: 20370682 [TBL] [Abstract][Full Text] [Related]
17. Heparan sulfate targeting strategy for enhancing liposomal drug accumulation and facilitating deep distribution in tumors. Kuo PH; Teng YH; Cin AL; Han W; Huang PW; Wang LH; Chou YT; Yang JL; Tseng YL; Kao M; Chang MD Drug Deliv; 2020 Dec; 27(1):542-555. PubMed ID: 32241176 [TBL] [Abstract][Full Text] [Related]
18. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study. Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748 [TBL] [Abstract][Full Text] [Related]
19. Lipid nanoemulsions loaded with doxorubicin-oleic acid ionic complex: characterization, in vitro and in vivo studies. Zhang X; Sun X; Li J; Zhang X; Gong T; Zhang Z Pharmazie; 2011 Jul; 66(7):496-505. PubMed ID: 21812324 [TBL] [Abstract][Full Text] [Related]
20. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo. Xiong XB; Huang Y; Lu WL; Zhang H; Zhang X; Zhang Q Pharm Res; 2005 Jun; 22(6):933-9. PubMed ID: 15948037 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]